153 related articles for article (PubMed ID: 1026347)
21. In vivo enhancement of 5-fluorouracil cytotoxicity to AKR leukemia cells by thymidine in mice.
Santelli G; Valeriote F
J Natl Cancer Inst; 1978 Sep; 61(3):843-7. PubMed ID: 278862
[TBL] [Abstract][Full Text] [Related]
22. Comparison of in vivo and in vitro effects of continuous exposure of L1210 cells to 6-thioguanine.
Maybaum J; Morgans CW; Hink LA
Cancer Res; 1987 Jun; 47(12):3083-7. PubMed ID: 3581060
[TBL] [Abstract][Full Text] [Related]
23. Combination chemotherapy of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine.
Neil GL; Berger AE; Bhuyan BK; DeSante DC
Cancer Res; 1976 Mar; 36(3):1114-20. PubMed ID: 56229
[TBL] [Abstract][Full Text] [Related]
24. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
Li ZR; Campbell J; Rustum YM
Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
[TBL] [Abstract][Full Text] [Related]
25. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
Schwartz SA; Morgenstern B; Capizzi RL
Cancer Res; 1982 Jun; 42(6):2191-7. PubMed ID: 7074600
[TBL] [Abstract][Full Text] [Related]
26. Partial synchronization of L1210 cells by 5-fluorouracil and its use in drug combinations.
Bhuyan BK; Blowers CL; Neil GL; Bono VH; Day KJ
Cancer Res; 1977 Sep; 37(9):3204-8. PubMed ID: 560250
[TBL] [Abstract][Full Text] [Related]
27. Contrasting cytotoxicity kinetics of 5-azacytidine and dihydro-5-azacytidine hydrochloride in L1210 leukemia in mice.
Presant CA; Coulter D; Valeriote F; Vietti TJ
J Natl Cancer Inst; 1981 Jun; 66(6):1151-4. PubMed ID: 6165854
[TBL] [Abstract][Full Text] [Related]
28. Effect of arabinosyl cytosine on granulopoietic colony formation by marrow cells from leukemic and non-leukemic patients.
Niho Y; Till JE; McCulloch EA
Exp Hematol; 1976 Mar; 4(2):63-9. PubMed ID: 1063075
[TBL] [Abstract][Full Text] [Related]
29. Cellular quantitation of in vivo effects of 1-beta-D-arabinofuranosylcytosine on leukemia L1210.
Edelstein M; Valeriote F; Vietti T
J Natl Cancer Inst; 1977 Apr; 58(4):941-7. PubMed ID: 845997
[TBL] [Abstract][Full Text] [Related]
30. Prolonged exposure to cytosine arabinoside in the presence of hematopoietic growth factors preferentially kills leukemic versus normal clonogenic cells.
Van Der Lely N; De Witte T; Muus P; Raymakers R; Preijers F; Haanen C
Exp Hematol; 1991 May; 19(4):267-72. PubMed ID: 2055291
[TBL] [Abstract][Full Text] [Related]
31. Enhanced capacity of cytosine-arabinoside-treated murine bone marrow to maintain hematopoiesis in long-term culture.
Ben-Ishay Z; Prindull G
Exp Hematol; 1988 Feb; 16(2):106-11. PubMed ID: 3276542
[TBL] [Abstract][Full Text] [Related]
32. Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein.
Fu CH; Martin-Aragon S; Weinberg KI; Ardi VC; Danenberg PV; Avramis VI
Cancer Chemother Pharmacol; 2001 Aug; 48(2):123-33. PubMed ID: 11561778
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
Kato Y; Saito M; Fukushima H; Takeda Y; Hara T
Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
[TBL] [Abstract][Full Text] [Related]
34. GM-CSF enhances sensitivity of leukemic clonogenic cells to long-term low dose cytosine arabinoside with sparing of the normal clonogenic cells.
De Witte T; Muus P; Haanen C; Van der Lely N; Koekman E; Van der Locht A; Blankenborg G; Wessels J
Behring Inst Mitt; 1988 Aug; (83):301-7. PubMed ID: 3071344
[TBL] [Abstract][Full Text] [Related]
35. Schedule-dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin.
Edelstein M; Vietti T; Valeriote F
Cancer Res; 1974 Feb; 34(2):293-7. PubMed ID: 4810905
[No Abstract] [Full Text] [Related]
36. Synchronization of L1210 leukemia with hydroxyurea infusion and the effect of subsequent pulse dose chemotherapy.
Moran RE; Straus MJ
Cancer Treat Rep; 1980 Jan; 64(1):81-6. PubMed ID: 7379059
[TBL] [Abstract][Full Text] [Related]
37. Kinetics of cytotoxicity of VM-26 and VP-16-213 on L1210 leukemia and hematopoietic stem cells.
Vietti TJ; Valeriote FA; Kalish R; Coulter D
Cancer Treat Rep; 1978 Sep; 62(9):1313-20. PubMed ID: 688275
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy of mouse leukemia L1210 by 1-beta-D-arabinofuranosylcytosine and 6-[(4-nitrobenzyl)thio]-9-beta-D-ribofuranosylpurine.
Cass CE; Muzik H; Paterson AR
Cancer Res; 1975 May; 35(5):1187-93. PubMed ID: 1120308
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous assay by six methods of the effect on haemopoietic precursor cells of adriamycin, methyl CCNU, 60Co gamma-rays, vinblastine, and cytosine arabinoside.
Blackett NM; Marsh JC; Gordon MY; Okell SF; Aguado M
Exp Hematol; 1978 Jan; 6(1):2-8. PubMed ID: 342260
[TBL] [Abstract][Full Text] [Related]
40. Cytosine arabinoside as a suicide agent for human colony forming cells.
Dresch C; El Kebir N; Metral J; Karsdorf A
Exp Hematol; 1983 Mar; 11(3):187-92. PubMed ID: 6832245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
